Abstract:<p>Nonalcoholic fatty liver disease (NAFLD) has emerged as a public health concern. To date, the mechanism of NAFLD progression remains unclear, and pharmacological treatment options are scarce. Traditional animal NAFLD models are limited in helping address these problems due to interspecies differences. Liver chips are promising for modeling NAFLD. However, pre-existing liver chips cannot reproduce complex physicochemical microenvironments of the liver effectively; thus, NAFLD modeling based on these chips is incomplete. Herein, we develop a biomimetic liver lobule chip (LC) and then establish a more accurate on-chip NAFLD model. The self-developed LC achieves dual blood supply through the designed hepatic portal vein and hepatic artery and the microtissue cultured on the LC forms multiple structures similar to <em>in vivo</em> liver. Based on the LC, NAFLD is modeled. Steatosis is successfully induced and more importantly, changing lipid zonation in a liver lobule with the progression of NAFLD is demonstrated for the first time on a microfluidic chip. In addition, the application of the induced NAFLD model has been preliminarily demonstrated in the prevention and reversibility of promising drugs. This study provides a promising platform to understand NAFLD progression and identify <a href="https://cn.bing.com/dict/search?q=drugs&FORM=BDVSP6&mkt=zh-cn">drugs</a> for treating NAFLD.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Statement of Significance</h3><p>Liver chips are promising for modeling nonalcoholic fatty liver disease (NAFLD). However, on-chip replicating liver physicochemical microenvironments is still a challenge. Herein, we developed a liver lobule chip with dual blood supply, achieving self-organized liver microtissue that is similar to in vivo tissue. Based on the chip, we successfully modeled NAFLD under physiologically differentiated nutrient supplies. For the first time, the changing lipid zonation in a single liver lobule with the early-stage progression of NAFLD was demonstrated on a liver chip. This study provides a promising platform for modeling liver-related diseases.</p>

Synergistic Modulation of a Tunable Microenvironment to Fabricate a Liver Fibrosis Chip for Drug Testing.

Metastasis-on-a-chip Mimicking the Progression of Kidney Cancer in the Liver for Predicting Treatment Efficacy

Hydrogel Microfluidic‐based Liver‐on‐a‐chip: Mimicking the Mass Transfer and Structural Features of Liver

Construction of a Liver Sinusoid Based on the Laminar Flow on Chip and Self-Assembly of Endothelial Cells

Development of a Biomimetic Liver Tumor-on-a-chip Model Based on Decellularized Liver Matrix for Toxicity Testing.

On-Chip Construction of Liver Lobule-like Microtissue and Its Application for Adverse Drug Reaction Assay.

A Microfluidic Lung-on-a-chip Based on Biomimetic Hydrogel Membrane

A Biomimetic Optical Cardiac Fibrosis-on-a-Chip for High-Throughput Anti-Fibrotic Drug Screening

A pumpless liver-on-a-chip for drug hepatotoxicity analysis

A 3D bio-printed spheroids based perfusion in vitro liver on chip for drug toxicity assays

Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply

Dynamic Liver Chip Based on Well-Coupled Microfluidics: An Accurate NASH Model for Drug Evaluation

Real-time monitoring of liver fibrosis through embedded sensors in a microphysiological system

Design and fabrication of an integrated 3D dynamic multicellular liver-on-a-chip and its application in hepatotoxicity screening

Insight to Biofabrication of Liver Microtissues for Disease Modeling: Challenges and Opportunities

A microvascularized in vitro liver model for disease modeling and drug discovery

Constructing biomimetic liver models through biomaterials and vasculature engineering

Protocol to generate human liver spheroids to study liver fibrosis induced by metabolic stress

Customizable Microfluidic Origami Liver‐on‐a‐Chip (oLOC)

Advanced Liver-on-a-Chip Model for Evaluating Drug Metabolism and Hepatotoxicity